CDX2 Antikörper (AA 1-30)

Produktnummer ABIN3030336

Produktdetails anti-CDX2 Antikörper

Target: CDX2 (Caudal Type Homeobox 2 (CDX2))

Bindungsspezifität: AA 1-30

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CDX2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Kreuzreaktivität (Details): Expected species reactivity: Mouse

Aufreinigung: Purified

Immunogen: A portion of amino acids 1-30 from the human protein was used as the immunogen for this CDX2 antibody.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Titration of the CDX2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the CDX2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Details zu CDX2

Target: CDX2 (Caudal Type Homeobox 2 (CDX2))

Andere Bezeichnung: CDX2 (CDX2 Produkte)

Synonyme: CDX2 antikoerper, MGC130987 antikoerper, cdx3-like antikoerper, CDX-3 antikoerper, CDX3 antikoerper, CDX-2 antikoerper, Cdx-2 antikoerper, caudal type homeobox 2 antikoerper, caudal type homeobox 2 L homeolog antikoerper, caudal type homeo box 2 antikoerper, CDX2 antikoerper, cdx2.L antikoerper, Cdx2 antikoerper

Hintergrund: The caudal type homeo box transcription factors 1 (CDX1) and 2 (CDX2) are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Increased CDX2 expression is associated with chronic atrophic gastritis. Detectable expression of CDX2 precedes expression of CDX1 during the progression of intestinal metaplasia, thus expression of CDX2 may trigger the initiation and development of intestinal metaplasia. Markedly reduced or absent CDX2 expression was noted by immunohistochemistry in 13 of 15 (87 % ) large cell minimally differentiated carcinomas (LCMDCs), whereas only 1 of the 25 (4 %) differentiated adenocarcinomas (DACs) showed reduced CDX2 expression. Thus, a significant decrease in human CDX1 and/or CDX2 expression may be associated with colorectal tumorigenesis.

UniProt: Q99626

Pathways: Peptide Hormone Metabolism, Stem Cell Maintenance